Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

insulin

Sanofi to develop a mobile app for insulin patients

Will work with therapeutic companion software company Voluntis

- PMLiVE

Type 2 diabetes can be reversed in just four months, say researchers

A controlled diet and a strict exercise regime could help cure type 2 diabetes

Sanofi reception

Sanofi adds to dupilumab evidence base as US approval nears

FDA to deliver verdict on atopic dermatitis drug

- PMLiVE

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

Sanofi reception

Sanofi buys into AZ drug for preventing RSV infections

Currently there are no approved drugs to treat RSV once established

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

Sanofi reception

Praluent can stay on market for now, says US court

Sanofi and Regeneron win appeal to suspended permanent injunction sought by Amgen

- PMLiVE

Sanofi appoints general manager UK

Hugo Fry previously served as chief marketing officer at Sanofi Pasteur

Sanofi reception

Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Competition to Roche’s blockbuster RA therapy heats up as Canada is first to licence new drug

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

Biogen’s corporate affairs SVP joins Sanofi

Kathleen Tregoning becomes executive vice president, external affairs

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links